Literature DB >> 25002527

Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.

Peng Ye1, Junsei Mimura2, Tomomi Okada3, Hideyo Sato3, Tao Liu1, Atsushi Maruyama1, Chikara Ohyama4, Ken Itoh1.   

Abstract

The ubiquitin-proteasome pathway degrades ubiquitinated proteins to remove damaged or misfolded protein and thus plays an important role in the maintenance of many important cellular processes. Because the pathway is also crucial for tumor cell growth and survival, proteasome inhibition by specific inhibitors exhibits potent antitumor effects in many cancer cells. xCT, a subunit of the cystine antiporter system xc (-), plays an important role in cellular cysteine and glutathione homeostasis. Several recent reports have revealed that xCT is involved in cancer cell survival; however, it was unknown whether xCT affects the cytotoxic effects of proteasome inhibitors. In this study, we found that two stress-inducible transcription factors, Nrf2 and ATF4, were upregulated by proteasome inhibition and cooperatively enhance human xCT gene expression upon proteasome inhibition. In addition, we demonstrated that the knockdown of xCT by small interfering RNA (siRNA) or pharmacological inhibition of xCT by sulfasalazine (SASP) or (S)-4-carboxyphenylglycine (CPG) significantly increased the sensitivity of T24 cells to proteasome inhibition. These results suggest that the simultaneous inhibition of both the proteasome and xCT could have therapeutic benefits in the treatment of bladder tumors.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25002527      PMCID: PMC4135628          DOI: 10.1128/MCB.00221-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  59 in total

Review 1.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Authors:  Jan Lewerenz; Sandra J Hewett; Ying Huang; Maria Lambros; Peter W Gout; Peter W Kalivas; Ann Massie; Ilse Smolders; Axel Methner; Mathias Pergande; Sylvia B Smith; Vadivel Ganapathy; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2012-08-03       Impact factor: 8.401

Review 2.  Glutathione metabolism and its implications for health.

Authors:  Guoyao Wu; Yun-Zhong Fang; Sheng Yang; Joanne R Lupton; Nancy D Turner
Journal:  J Nutr       Date:  2004-03       Impact factor: 4.798

3.  Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation.

Authors:  Hideyo Sato; Shinobu Nomura; Kanako Maebara; Kanako Sato; Michiko Tamba; Shiro Bannai
Journal:  Biochem Biophys Res Commun       Date:  2004-12-03       Impact factor: 3.575

4.  The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation.

Authors:  Paul Nioi; Truyen Nguyen; Philip J Sherratt; Cecil B Pickett
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

5.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

Review 6.  Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application.

Authors:  Xiaoping Yang; Thomas W Flaig
Journal:  Int Braz J Urol       Date:  2010 May-Jun       Impact factor: 1.541

7.  Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma.

Authors:  Hiroki Kinoshita; Hirohisa Okabe; Toru Beppu; Akira Chikamoto; Hiromitsu Hayashi; Katsunori Imai; Kosuke Mima; Shigeki Nakagawa; Takatsugu Ishimoto; Keisuke Miyake; Naomi Yokoyama; Takatoshi Ishiko; Hideo Baba
Journal:  Oncol Rep       Date:  2012-11-30       Impact factor: 3.906

Review 8.  Therapeutic approaches to bladder cancer: identifying targets and mechanisms.

Authors:  Richard J Cote; Ram H Datar
Journal:  Crit Rev Oncol Hematol       Date:  2003-06-27       Impact factor: 6.312

9.  The present and future burden of urinary bladder cancer in the world.

Authors:  Martine Ploeg; Katja K H Aben; Lambertus A Kiemeney
Journal:  World J Urol       Date:  2009-02-15       Impact factor: 4.226

10.  The resistance mechanisms of proteasome inhibitor bortezomib.

Authors:  Shuqing Lü; Jianmin Wang
Journal:  Biomark Res       Date:  2013-03-01
View more
  83 in total

1.  The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.

Authors:  Pranavi Koppula; Yilei Zhang; Jiejun Shi; Wei Li; Boyi Gan
Journal:  J Biol Chem       Date:  2017-06-19       Impact factor: 5.157

2.  Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase.

Authors:  Dana M Gwinn; Alex G Lee; Marcela Briones-Martin-Del-Campo; Crystal S Conn; David R Simpson; Anna I Scott; Anthony Le; Tina M Cowan; Davide Ruggero; E Alejandro Sweet-Cordero
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

3.  Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.

Authors:  Kewen Hu; Kun Li; Jing Lv; Jie Feng; Jing Chen; Haigang Wu; Feixiong Cheng; Wenhao Jiang; Jieqiong Wang; Haixiang Pei; Paul J Chiao; Zhenyu Cai; Yihua Chen; Mingyao Liu; Xiufeng Pang
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 4.  Mechanisms of NRF2 activation to mediate fetal hemoglobin induction and protection against oxidative stress in sickle cell disease.

Authors:  Xingguo Zhu; Aluya R Oseghale; Lopez H Nicole; Biaoru Li; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-23

5.  In silico characterization of residues essential for substrate binding of human cystine transporter, xCT.

Authors:  Monika Sharma; C R Anirudh
Journal:  J Mol Model       Date:  2019-11-09       Impact factor: 1.810

6.  A Homeostatic Shift Facilitates Endoplasmic Reticulum Proteostasis through Transcriptional Integration of Proteostatic Stress Response Pathways.

Authors:  Liam Baird; Tadayuki Tsujita; Eri H Kobayashi; Ryo Funayama; Takeshi Nagashima; Keiko Nakayama; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2017-02-01       Impact factor: 4.272

Review 7.  xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling.

Authors:  Jinyun Liu; Xiaojun Xia; Peng Huang
Journal:  Mol Ther       Date:  2020-09-02       Impact factor: 11.454

8.  The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11.

Authors:  Tong Liu; Le Jiang; Omid Tavana; Wei Gu
Journal:  Cancer Res       Date:  2019-02-01       Impact factor: 12.701

9.  Glucose deprivation induces chemoresistance in colorectal cancer cells by increasing ATF4 expression.

Authors:  Ya-Ling Hu; Yuan Yin; He-Yong Liu; Yu-Yang Feng; Ze-Hua Bian; Le-Yuan Zhou; Ji-Wei Zhang; Bo-Jian Fei; Yu-Gang Wang; Zhao-Hui Huang
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

10.  xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells.

Authors:  Peng Zhang; Wei Wang; Zhenhui Wei; L I Xu; Xuanning Yang; Yuanhong DU
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.